The overall response rate among treatment-naive patients was 68%, while it was 41% among previously treated patients, the company said.
The most common treatment-related adverse events were peripheral edema, nausea and vomiting.
The study was conducted by Novartis (NVS), which has exclusive worldwide development and commercialization rights to Tabrecta. Under the agreement, Incyte is eligible to receive more than $500 million in milestones and 12% to 14% of royalties on global net sales of the drug.
Price: 95.44, Change: +2.47, Percent Change: +2.66
|Significant Insider Sales Reported in Shares of KalV...|
|Insider Sale at Mastercard (MA) Continues Selling Trend|
|Insider Selling at Illumina (ILMN) Continues with Si...|
|Insider Selling in Salesforce.com (CRM) Shares Conti...|
|VeriSign (VRSN) sees Significant Insider Sales Exten...|